Kornimate/medical-research-clean huggingface dataset:
online dietary and resistance training to improve physical function in older cancer survivors, e-proof trial

Conditions: Anatomic Stage I Breast Cancer AJCC V8; Anatomic Stage II Breast Cancer AJCC V8; Anatomic Stage III Breast Cancer AJCC V8; Stage I Colorectal Cancer AJCC V8; Stage I Prostate Cancer AJCC V8; Stage II Colorectal Cancer AJCC V8; Stage II Prostate Cancer AJCC V8; Stage III Colorectal Cancer AJCC V8; Stage III Prostate Cancer AJCC V8

Summary: this phase i trial tests the feasibility, acceptability, and preliminary effectiveness of online dietary and resistance training to improve physical function in older (greater than or equal to 65-years old) cancer survivors. declines in adequate protein and calorie intake results in faster loss of muscle mass and physical functioning in older adults. a novel approach to improving physical function in older cancer survivors (ocs) is to utilize online, tailored education and counseling from registered dietitians and exercise scientists, to improve dietary intake (protein intake, diet quality) and participation in resistance exercise. the purpose of this study is to help researchers learn whether an online dietary and resistance training intervention improves diet, exercise, physical function, and health outcomes in ocs.

primary objectives: i. determine the feasibility and acceptability of implementing a 12-week online dietary and resistance training randomized trial with 70 older cancer survivors. ii. examine the preliminary efficacy of this 12-week online dietary and resistance training intervention with the intervention participants. outline: patients are randomized to 1 of 2 arms. arm 1: patients participate in online nutritional counseling over 30 minutes in weeks 1, 3, 5, 7, 9, and 11, and participate in online resistance training sessions weekly over 30 minutes in weeks 1-6 and biweekly at weeks 8, 10, and 12. patients also receive educational materials at baseline. arm 2: patients receive educational materials at baseline. after completion of study intervention, patients are followed up at 3 months.

Eligibility criteria:
inclusion criteria: * \>= 65 years of age * a primary diagnosis of stage i-iii breast, colorectal, and prostate cancer * completion of primary curative treatment * reported at least 1 physical function limitation on the rand-36 physical function subscale (pfss) ("limited a little", "limited a lot") * no evidence of progressive disease or second cancers * community-dwelling * able to provide consent exclusion criteria: * currently receive cancer treatment (e.g., chemotherapy, radiation) * have liver and/or renal disease limiting their protein intake * are under the care of a registered dietician (rd)/nutritionist * participating in other diet/exercise interventions * consume protein supplements * have contraindications to unsupervised exercise (e.g., walker/wheelchair use)
an evaluation of the novel traminer sequence by comparison to late gadolinium enhancement images

Conditions: Myocardial Fibrosis; Cardiovascular Disease

Summary: * the purpose of this study is to show that the novel traminer (t(rho) and magnetization transfer and inversion recovery) sequence provides at least as good visualization and detection of sub-endocardial scarring, fibrosis, and acute infarction as the current gold standard inversion recovery (ir) turbo-flash sequence. * the hypothesis is that the traminer sequence has the same or higher sensitivity in detecting small sub-endocardial scarring than the inversion recovery segmented gradient echo sequence known as ir-turbo fast low angle shot (ir turbo-flash), which is the accepted current gold standard for the detection of myocardial viability.


Eligibility criteria:
inclusion criteria: * adults ≥18 years of age referred for a cardiac mri with gadolinium enhancement only at advocate lutheran general hospital exclusion criteria: * \<18 years old, * adults unable to consent * adults for whom the mri has not been previously scheduled * adults with an order for any mri other than cardiac mri with gadolinium enhancement
ed90 of norepinephrine and phenylephrine infusions under intensive treatment in preeclamptic patients

Conditions: Adverse Effect

Summary: the objective of this study is to investigate the ed90 of norepinephrine and phenylephrine infusions for preventing postspinal anesthesia hypotension under intensive treatment in preeclamptic patients during cesarean section

post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. the incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. the 2016 asa guidelines for obstetric anesthesia suggest avoiding hypotension following spinal anesthesia in women and emphasize the use of vasopressors, specifically alpha-receptor agonists, as the preferred strategy to prevent and manage post-spinal anesthesia hypotension. the 2018 international consensus in the united kingdom and northern ireland recommends maintaining maternal systolic blood pressure above 90% of the baseline value following lumbar anesthesia, while avoiding dropping below 80% of the baseline value. currently, the threshold for maintaining blood pressure above 80% of the baseline value is widely adopted as a standard; however, limited evidence supports the advantage of sustaining maternal blood pressure above 90% of the baseline value. the objective of this study is to investigate the ed90 of norepinephrine and phenylephrine infusions for preventing postspinal anesthesia hypotension under intensive treatment in preeclamptic patients during cesarean section

Eligibility criteria:
inclusion criteria: * 18-45 years * primipara or multipara * singleton pregnancy ≥32 weeks * american society of anesthesiologists physical status classification i to iii * scheduled for cesarean section under spinal anesthesia exclusion criteria: * baseline blood pressure ≥160 mmhg * body height \< 150 cm * body weight \> 100 kg or body mass index (bmi) ≥ 40 kg/m2 * eclampsia or chronic hypertension * hemoglobin \< 7g/dl * fetal distress, or known fetal developmental anomaly
incidence of snakebite associated thrombotic microangiopathy & role of peripheral blood smear as a predictor of clinical outcome

Conditions: SNAKEBITE; THROMBOTIC MICROANGIOPATHY; SCHISTOCYTES

Summary: the aim of this study is to find the overall incidence of thrombotic microangiopathy in snakebite victims. as we know snakebite is a common in tropical regions. many a times the early diagnosis of tma is missed and precious time which could have helped in improving the patient prognosis is lost. also via this study we wish to learn the role of cost effective test like peripheral smear which could help learn morphological picture of red blood cells and thus help in early prediction of patients clinical prognosis.

all snakebite patients brought to emergency department with history of bite and prolonged whole blood clotting time (wbct) will be included in the study . their samples for hemogram, rft and ldh would be collected in corresponding tubes . from sample for hemogram a peripheral blood smear (pbs) would be prepared , also the sample would be checked for direct coomb's test (dct) positivity. dct positive patients would be excluded from study . also patients who received blood or blood components from outside hospital or patients with known history of hemolytic disease or patients on anti platelets or anticoagulants would also be excluded from this study . thus patients who meet the exclusion and inclusion criteria would be followed up after 48 hours and their hemogram , rft and ldh would be re assessed to check for presence of hemolysis , thrombocytopenia and acute kidney injury(aki) .from the hemogram sample pbs would be prepared to check for presence of schistocytes. here we aim to study for incidence of tma - defined as presence of maha( microangiopathic hemolytic anemia ) , thrombocytopenia and presence of aki . maha is detected as drop of hb, presence of schistocytes in pbs , increase in ldh and increase in retic count. india is a tropical country and the southern state of kerala , this study is done with the purpose of finding the prevalence of tma among patients of snakebite brought to a tertiary care centre. most often the victims are farmers or people from middle class. a cost effective test such as peripheral smear can help in predicting the prognosis and thereby aid in deciding whether the patient should require a multi disciplinary treatment early on and thereby play a pivotal role in saving patient life as well as provide an economical solution.

Eligibility criteria:
inclusion criteria: * all patients with a history of snakebite and with prolonged wbct. exclusion criteria: * patients administered with blood or blood components prior to admission * known case of bleeding disorders * known case of haemolytic anaemia * patients on antiplatelets or anticoagulants

Keywords: tma, peripheral blood smear(pbs)
efficacy of keyhole approach to carpal tunnel syndrome under ambulatory strategy

Conditions: Carpal Tunnel Syndrome; Entrapment Neuropathy

Summary: prospective controlled clinical trial in which a minimally invasive microsurgical approach was used following the keyhole principle in 55 patients and 65 hands under local anesthesia and ambulatory strategy. all patients included in the study had an average of 3 months disease course and were considered refractory to conservative treatment. patients were evaluated with stringent inclusion criteria with the levine severity and functional status scale with a 2 year follow-up. descriptive outcomes on the efficiency of this procedure are reported.

prospective clinical study to analyze 55 patients with carpal tunnel syndrome treated with open minimally invasive approach in 65 hands, using local anesthesia without tourniquet and in an ambulatory setting.

Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis who had neurologic exam, electromyography, cervical spine x rays showing no structural disturbances and with at least 3 months of persistent pain refractory to medical management and physical therapy. exclusion criteria: * patients with a history of direct trauma or orthopedic lesions in the carpal region, endocrine and/or metabolic disturbances (hypothyroidism, diabetes) and those that had previous local administration of steroids were excluded.

Keywords: microsurgical treatment pain dexterity phalen sign functional status
a comparative study of two daily disposable contact lenses in higher myopia subjects

Conditions: Refractive Error; Myopia

Summary: the purpose of this study is to compare the change from baseline in central corneal curvature at one week, between 2 silicone hydrogel lenses, in higher myopic subjects.

participants were expected to attend 4 office visits. visit 1 was the screening/enrollment visit. at visit 2 (baseline visit), participants were randomized and the study lenses were trial fit. at visit 3 (dispense visit), participants received study lenses for approximately 1 week of wear. visit 4 was the exit visit. expected duration of participation in the study was 3 weeks.

Eligibility criteria:
inclusion criteria: * sign informed consent document; * higher degree of myopia in both eyes, i.e. habitual contact lens power between -10.00 diopters (d) and -17.00d; * best corrected distance visual acuity greater than or equal to 20/30 in each eye (measured with either spectacle refraction or habitual contact lenses plus over refraction); * manifest astigmatism less than or equal to -1.00d; * soft contact lens wear in both eyes at least 5 days per week and at least 8 hours per day; * other protocol-defined inclusion criteria may apply. exclusion criteria: * pregnant or lactating; * eye injury or surgery within twelve weeks immediately prior to enrollment; * any ocular condition that contraindicates contact lens wear; * history of herpetic keratitis; * any use of systemic or ocular medications for which contact lens wear could be contraindicated, including any use of topical ocular medications that would require instillation during contact lens wear, except for approved lubricating drops; * clinical significant dry eye not responding to treatment; * previous corneal or refractive surgery or irregular cornea; * requires reading glasses; * participation in a clinical trial (including contact lens or contact lens care product) within the previous 30 days; * wears habitual lenses in an extended wear modality (routinely sleeps in lenses overnight for 1 night per week or more) over the last 3 months prior to enrollment; * other protocol-defined exclusion criteria may apply.

Keywords: contact lenses nearsightedness corneal curvature k-reading high minus spectacle refraction
effect of auditory and tactile-kinesthetic stimulation on preterm neonates

Conditions: Prematurity

Summary: the study was conducted at a level ii special care nursery of the moi teaching \& referral hospital, an academic hospital in the western region of kenya. a sample of 108 preterm neonates who met eligibility criteria were studied (36 in auditory group, 36 in tactile-kinesthetic stimulation group, and 36 in control group). auditory group listened to recorded maternal voice while tactile-kinesthetic group received massage and joint movements.the interventions were provided for 15 minutes, 3 times a day for 10 days while outcome measures were observed for 21 days. the neonates in the control group received standard neonatal care and were observed for outcome measures as those in the intervention groups.

the study was aimed to determine the effect of auditory stimulation using recorded maternal voice and tactile-kinesthetic stimulation on physiological parameters, physical growth and behavioral development of preterm neonates. three groups were involved; auditory stimulation, tactile-kinesthetic stimulation and control. a quasi-experimental design was used to recruit 108 study subjects (36 in each group). a trained researcher conducted the stimulation in the intervention groups and two research assistants did the data entry. the research assistants were blinded to aim of study, group assignments, and interventions received by preterm neonates. preterm neonates baseline characteristics and clinical data were obtained at initial contact. physiological parameters (heart rate, oxygen saturation and body temperature) were monitored using a cardio-respiratory monitor (codec patient monitor cms6000). respiratory rate was measured by counting breaths per minute by the research assistant. the parameters were monitored and recorded before, during and after stimulation in the intervention groups. the control group had the measurement recorded in the morning, afternoon and evening. physical growth was assessed using weight measurement. neonates are weighed daily in the nursery and data on weight was entered by research assistants on alternate days. neonatal behavioral assessment scale (nbas) was used to assess behavior at initial contact, day 10, 17 and 24.

Eligibility criteria:
inclusion criteria: * on breast milk or formula feeds * born 28 to 37 weeks gestational age * ≥1000grams. the gestation was limited to ≥ 28 weeks and ≥1000grams based on significant neonatal mortality rate in neonates born before 28 weeks gestation and/or weighing \<1000grams in mtrh (njuguna et al., 2015). exclusion criteria: * critically ill and those on continuous positive airway pressure (cpap) * had neonatal infections including severe sepsis or necrotizing enterocolitis.

Keywords: maternal voice and tactile-kinesthetic stimulation
a study to assess change in disease activity and adverse events (ae)s in adult participants with multiple myeloma receiving etentamig (abbv-383) as an intravenous (iv) infusion alone or in combination with oral, iv, subcutaneous daratumumab; lenalidomide; dexamethasone; carfilzomib

Conditions: Multiple Myeloma

Summary: multiple myeloma (mm) is a cancer of the blood's plasma cells. the cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. treatments are available, but mm can come back (relapsed) or may not get better (refractory) with treatment. this is a study to determine the safety, efficacy, and pharmacokinetics of etentamig in adult participants with mm. etentamig is an investigational drug being developed for the treatment of mm. this study is broken into 4 substudies and each substudy consists of a dose escalation phase and dose expansion phase. participants will receive escalating doses of etentamig alone or in combination with daratumumab and lenalidomide (dr), carfilzomib and dexamethasone (kd) or lenalidomide (r). this will be followed by etentamig at the dose levels established during the escalation phases alone or in combination with dr, kd, r. the participants can also receive daratumumab, lenalidomide and dexamethasone (drd), r, or daratumumab, carfilzomib, and dexamethasone (dkd) as a comparator in the dose expansion phases. around 440 adult participants with mm will be enrolled at approximately 50 sites worldwide in all substudies, participants will receive escalating doses of etentamig as intravenous (iv) infusions, alone or in combination with dr, r or kd, followed by iv infusions of etentamig at the dose levels established during the escalation phases alone or in combination with iv and oral drd, dkd, or r. the study duration is approximately 130 months. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance of \<= 1. * confirmed diagnosis of multiple myeloma (mm) according to the international myeloma working group (imwg) diagnostic criteria with either newly diagnosed or relapsed or refractory (rr) mm, depending on the substudy. exclusion criteria: * participant who has known active central nervous system involvement of mm. * participant who has known active infection as outlined in the protocol.

Keywords: multiple myeloma, etentamig, abbv-383, cancer daratumumab lenalidomide dexamethasone carfilzomib
outcomes of laparoscopic sleeve gastrectomy

Conditions: Bariatric Surgery Candidate; Laparoscopic Sleeve Gastrectomy; Obesity, Morbid

Summary: the aim of this study is to assess 5 year long-term outcomes of laparoscopic sleeve gastrectomy emphasizing weight loss and modification of comorbidities such as type 2 diabetes mellitus, hypertension and gastroesophageal reflux disease from a developing country, turkey. prospectively-collected patient data will retrospectively reviewed. to measure the efficacy of the procedure, we will calculate the excess weight loss percentage (ewl %). effective weight loss after lsg will accepted as more than 50%. the changes in the status of the type 2 diabetes mellitus, hypertension, gastroesophageal reflux disease will be observed.


Eligibility criteria:
inclusion criteria: * inclusion criteria were, patients between 18 to 65 years old, initial body mass index (bmi) 40 kg/m2 or bmi of 35 kg/m2 in the presence of additional comorbidity and failure of conservative treatment for 2 years. exclusion criteria: * none
risk factors of ascending aortic atheromatous

Conditions: Ascending Aortic Atheromatous Plaque

Summary: background incidence of perioperative stroke in cardiac surgery is 2.6-5.2%. ascending aortic atheromatous plaque and stroke are strongly associated. propose of study to determine incidence of ascending aortic atheroma in thai people to identify risk factors which associated with ascending aortic atheroma methodology after received standard general anesthesia and start sternotomy. epiaortic scan will be performed by surgeon use l15-7i phillips® ultrasound probe cover with sterile cover. five standard epiaortic views will be collected. epiaortic clips will be review and determine about atheroma by two qualified echocardiographers. atheroma more than third grade will defined to significant. potential risk factors of atheroma will be gather from medical record to assess the relationship between risk factors and atheroma a univariate analysis was performed using an unpaired t-test and a chi-square test. for higher accuracy regarding the impact of single risk factors, a multiple logistic regression analysis was also performed.


Eligibility criteria:
inclusion criteria: age ≥ 18 years schedule to cardiac surgery with sternotomy exclusion criteria: abnormal ascending aortic anatomy such as: dissection, aneurysm
high light and low light dose pdt in glioma

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. when the drug is active, tumor cells are killed. giving photodynamic therapy after surgery may kill any remaining tumor cells. purpose: this randomized clinical trial is studying two different light doses of photodynamic therapy using porfimer sodium to compare how well they work in treating patients who are undergoing surgery for recurrent malignant astrocytoma.

objectives: * compare survival of patients undergoing surgical resection for recurrent high-grade malignant supratentorial astrocytoma treated with intraoperative high vs low light dose photodynamic therapy using porfimer sodium. outline: this is a randomized, multicenter study. patients are stratified according to participating center. patients are randomized to 1 of 2 treatment arms. all patients receive porfimer sodium iv. one day later, patients undergo craniotomy and tumor resection. * arm i: during surgery, patients receive low light dose photodynamic therapy. * arm ii: during surgery, patients receive high light dose photodynamic therapy. after completion of study treatment, patients are followed at 1 day, 6 weeks, and 3 months and then every 3 months for up to 2 years. projected accrual: approximately 120 patients will be accrued for this study within 4-5 years.

Eligibility criteria:
disease characteristics: * histologically confirmed malignant supratentorial astrocytoma, glioblastoma, or mixed oligo-astrocytoma * grade 3 or 4 tumor, defined as presence of ≥ 2 of the following features: * nuclear atypia * mitosis * endothelial proliferation * necrosis * recurrent disease * failed prior surgery and radiotherapy * tumor suitable for radical resection by imaging studies patient characteristics: age * 18 and over performance status * karnofsky 60-100% life expectancy * at least 3 months hematopoietic * not specified hepatic * not specified renal * not specified other * not pregnant or nursing * fertile patients must use effective contraception * willing to avoid direct sun-light exposure for 6 weeks after photodynamic therapy prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * see disease characteristics surgery * see disease characteristics

Keywords: adult mixed glioma adult anaplastic astrocytoma recurrent adult brain tumor adult giant cell glioblastoma adult gliosarcoma